Table 4.
Comparing incremental cost effectiveness ratios of different treatment pathways for advanced hepatocellular carcinoma and assessing the net benefit
| Regimen | Cost, USD | QALYs | ICERs compared to |
Net benefit |
|||
|---|---|---|---|---|---|---|---|
| lowest cost (C) | next lowest cost | regimen Dc | USD 150,000/QALY | USD 300,000/QALY | |||
| C | 128,903.33 | 0.566 | - | - | - | −44,003.33 | 40,896.67 |
| D | 136,397.20 | 0.573 | 1,070,553.0 | 1,070,553.0 | - | −50,447.20 | 35,502.80 |
| G | 140,419.08 | 0.610 | 261,721.6 | 108,699.5 | 108,699.5 | −48,919.08 | 42,580.92 |
| H | 146,352.27 | 0.615 | 356,100.8 | 1,186,638.0 | 237,025.48 | −54,102.27 | 38,147.73 |
| E | 152,919.47 | 0.597 | 774,714.2 | SDb | - | −63,369.47 | 26,180.53 |
| F | 155,529.84 | 0.602 | 739,625.3 | - | - | −65,229.84 | 25,070.16 |
| A | 145,018.96 | 0.549 | dominateda | - | - | - | - |
| B | 148,669.18 | 0.556 | dominateda | - | - | - | - |
a
Dominated by the lowest-cost regimen with respect to QALYs.
b
SD = Strong dominance by lower-cost regimen H.
c
Excludes regimens E and F since they have-SD compared to the next lower cost regimen, H.